CSL Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 5/6

CSL verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 3.2%, während die Gewinne der Branche Biotechs jährlich um gewachsen und zwar um 13.2%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 11.2%. Die Eigenkapitalrendite von CSL beträgt 14% und die Nettomargen betragen 17.9%.

Wichtige Informationen

3.2%

Wachstumsrate der Gewinne

1.6%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie	9.6%
Wachstumsrate der Einnahmen	11.2%
Eigenkapitalrendite	14.0%
Netto-Marge	17.9%
Nächste Ertragsaktualisierung	10 Feb 2025

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Aufschlüsselung der Einnahmen und Ausgaben

Wie CSL Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

CHIA:CSL Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
30 Jun 24	14,800	2,642	2,381	1,428
31 Mar 24	14,490	2,557	2,305	1,386
31 Dec 23	14,179	2,472	2,277	1,312
30 Sep 23	13,745	2,333	2,317	1,274
30 Jun 23	13,310	2,194	2,308	1,266
31 Mar 23	12,507	2,156	2,168	1,265
31 Dec 22	11,705	2,118	2,028	1,263
30 Sep 22	11,133	2,186	1,839	1,210
30 Jun 22	10,562	2,255	1,649	1,156
31 Mar 22	10,587	2,290	1,711	1,108
31 Dec 21	10,612	2,325	1,773	1,060
30 Sep 21	10,461	2,350	1,742	1,031
30 Jun 21	10,310	2,375	1,712	1,001
31 Mar 21	10,145	2,520	1,612	953
31 Dec 20	9,980	2,665	1,511	904
30 Sep 20	9,565	2,384	1,550	913
30 Jun 20	9,151	2,103	1,588	922
31 Mar 20	9,048	2,054	1,557	904
31 Dec 19	8,944	2,006	1,527	886
30 Sep 19	8,742	1,962	1,484	859
30 Jun 19	8,539	1,919	1,442	832
31 Mar 19	8,406	1,861	1,441	791
31 Dec 18	8,274	1,803	1,441	751
30 Sep 18	8,094	1,766	1,371	726
30 Jun 18	7,915	1,729	1,301	702
31 Mar 18	7,666	1,674	1,251	713
31 Dec 17	7,417	1,618	1,200	723
30 Sep 17	7,182	1,478	1,191	695
30 Jun 17	6,947	1,337	1,182	667
31 Mar 17	6,802	1,333	1,118	642
31 Dec 16	6,656	1,329	1,055	617
30 Sep 16	6,386	1,286	1,033	615
30 Jun 16	6,115	1,242	1,011	614
31 Mar 16	5,983	1,324	954	564
31 Dec 15	5,850	1,406	897	513
30 Sep 15	5,654	1,392	841	488
30 Jun 15	5,459	1,379	786	463
31 Mar 15	5,482	1,366	768	467
31 Dec 14	5,505	1,354	750	471
30 Sep 14	5,420	1,330	773	468
30 Jun 14	5,335	1,307	797	466
31 Mar 14	5,189	1,270	803	466
31 Dec 13	5,042	1,233	810	466

Qualität der Erträge: CSL hat hohe Qualitätseinkünfte.

Wachsende Gewinnspanne: CSLDie aktuellen Gewinnspannen (17.9%) sind höher als im letzten Jahr (16.5%).

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: CSLIn den letzten 5 Jahren sind die Gewinne von 3.2% jährlich gestiegen.

Beschleunigtes Wachstum: CSLDas Gewinnwachstum des Unternehmens im letzten Jahr (20.4%) übertrifft seinen 5-Jahres-Durchschnitt (3.2% pro Jahr).

Erträge im Vergleich zur Industrie: CSL Das Gewinnwachstum im vergangenen Jahr (20.4%) übertraf das der Branche Biotechs 4% .

Eigenkapitalrendite

Hohe Eigenkapitalrendite: CSLDie Eigenkapitalrendite des Unternehmens (14%) wird als niedrig angesehen.

CSL Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Full year 2024 earnings released: EPS: US$5.47 (vs US$4.55 in FY 2023)

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

First half 2024 earnings released: EPS: US$3.94 (vs US$3.37 in 1H 2023)

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

Full year 2023 earnings released: EPS: US$4.55 (vs US$4.81 in FY 2022)

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

Recent updates

MD, CEO & Executive Director recently sold AU$1.1m worth of stock

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

Upcoming dividend of US$1.45 per share

Final dividend of US$1.45 announced

Full year 2024 earnings released: EPS: US$5.47 (vs US$4.55 in FY 2023)

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

Now 21% undervalued after recent price drop

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Now 20% undervalued

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings released: EPS: US$3.94 (vs US$3.37 in 1H 2023)

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

Now 22% undervalued

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

Upcoming dividend of US$1.29 per share at 1.4% yield

Independent Non-Executive Chairman recently sold AU$5.6m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

Full year 2023 earnings released: EPS: US$4.55 (vs US$4.81 in FY 2022)

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

Upcoming dividend of US$1.07 per share at 1.1% yield

First half 2023 earnings released: EPS: US$3.37 (vs US$3.85 in 1H 2022)

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

Independent Non Executive Director recently bought AU$74k worth of stock

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

Non-Independent Non-Executive Director recently sold AU$6.4m worth of stock

Upcoming dividend of US$1.18 per share

CSL Limited Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)

Full year 2022 earnings released: EPS: US$4.81 (vs US$5.22 in FY 2021)

CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022

Now 20% undervalued

Now 21% undervalued after recent price drop

Upcoming dividend of US$1.04 per share

Independent Non-Executive Director recently bought AU$54k worth of stock

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

CSL Limited Provides Earnings Guidance for the Fiscal Year 2022

CSL Limited has completed a Follow-on Equity Offering in the amount of AUD 750.028364 million.

CSL Limited (ASX:CSL) entered into a definitive agreement to launch public tender offer to acquire Vifor Pharma AG (SWX:VIFN) from Patinex AG and other for CHF 10.9 billion.

Vifor Pharma and CSL Confirm Merger Talks

Centerview Reportedly Role in Vifor Sale

Vifor Says Regularly in Talks with Other Market Participants After Reports

Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine

MD, CEO & Executive Director recently sold AU$4.4m worth of stock

MD, CEO & Executive Director recently sold AU$4.8m worth of stock

High number of new directors

Upcoming dividend of US$1.18 per share

Full year 2021 earnings released: EPS US$5.22 (vs US$4.63 in FY 2020)

CSL Limited Provides Financial Guidance for Fiscal 2022

Independent Non-Executive Director Shah Hussain has left the company

Seqirus Announces Health Canada Approval of Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People Two Years of Age and Older